API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
0
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
Details:
Through the acquisition, Corona Remedies gains right for the leading muscle relaxant brand Myoril (thiocolchicoside) and its extensions such as Myoril Plus (ketoprofen and thiocolchicoside) to treat muscular pain.
Lead Product(s): Thiocolchicoside
Therapeutic Area: Musculoskeletal Product Name: Myoril
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: CORONA remedies
Deal Size: $28.5 million Upfront Cash: Undisclosed
Deal Type: Acquisition June 28, 2023